Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mika Aoyagi

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|March 12, 2015
Trapping Poly(ADP-Ribose) PolymeraseYuqiao Shen, Mika Aoyagi-Scharber, Bing Wang
The EMBO Journal|February 8, 2003
Structural basis for endothelial nitric oxide synthase binding to calmodulinMika Aoyagi, Andrew S Arvai, John A Tainer, et al.
Plos One|July 7, 2018
Utilizing ExAC to assess the hidden contribution of variants of unknown significance to Sanfilippo Type B incidenceWyatt T Clark, G Karen Yu, Mika Aoyagi-Scharber, et al.
Journal of Medicinal Chemistry|December 15, 2015
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer AgentBing Wang, Daniel Chu, Ying Feng, et al.
Biochemical Society Symposium|March 22, 2005
Radical reactions of nitric oxide synthasesDennis J Stuehr, Chin-Chuan Wei, Jerome Santolini, et al.
Acta Crystallographica. Section F, Structural Biology Communications|September 9, 2014
Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinoneMika Aoyagi-Scharber, Anna S Gardberg, Bryan K Yip, et al.
Protein Science : a Publication of the Protein Society|November 25, 2006
Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family proteinMika Aoyagi, Dayong Zhai, Chaofang Jin, et al.
Journal of Medicinal Chemistry|May 6, 2010
Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic interventionAnton V Cheltsov, Mika Aoyagi, Alexander Aleshin, et al.
Plos One|January 19, 2019
BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesisGouri Yogalingam, Amanda R Luu, Heather Prill, et al.
Molecular Therapy. Methods & Clinical Development|July 17, 2019
Differential Uptake of NAGLU-IGF2 and Unmodified NAGLU in Cellular Models of Sanfilippo Syndrome Type BHeather Prill, Amanda Luu, Bryan Yip, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
The Journal of Pharmacology and Experimental Therapeutics|March 12, 2015
Trapping Poly(ADP-Ribose) PolymeraseYuqiao Shen, Mika Aoyagi-Scharber, Bing Wang
The EMBO Journal|February 8, 2003
Structural basis for endothelial nitric oxide synthase binding to calmodulinMika Aoyagi, Andrew S Arvai, John A Tainer, et al.
Plos One|July 7, 2018
Utilizing ExAC to assess the hidden contribution of variants of unknown significance to Sanfilippo Type B incidenceWyatt T Clark, G Karen Yu, Mika Aoyagi-Scharber, et al.
Journal of Medicinal Chemistry|December 15, 2015
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer AgentBing Wang, Daniel Chu, Ying Feng, et al.
Biochemical Society Symposium|March 22, 2005
Radical reactions of nitric oxide synthasesDennis J Stuehr, Chin-Chuan Wei, Jerome Santolini, et al.
Acta Crystallographica. Section F, Structural Biology Communications|September 9, 2014
Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinoneMika Aoyagi-Scharber, Anna S Gardberg, Bryan K Yip, et al.
Protein Science : a Publication of the Protein Society|November 25, 2006
Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family proteinMika Aoyagi, Dayong Zhai, Chaofang Jin, et al.
Journal of Medicinal Chemistry|May 6, 2010
Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic interventionAnton V Cheltsov, Mika Aoyagi, Alexander Aleshin, et al.
Plos One|January 19, 2019
BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesisGouri Yogalingam, Amanda R Luu, Heather Prill, et al.
Molecular Therapy. Methods & Clinical Development|July 17, 2019
Differential Uptake of NAGLU-IGF2 and Unmodified NAGLU in Cellular Models of Sanfilippo Syndrome Type BHeather Prill, Amanda Luu, Bryan Yip, et al.
Pageof 2